This study shows that two cannabinoids, Δ 9 -tetrahydrocannabinol (THC) and anandamide, induce dose-related immunosuppression in both the primary and secondary in vitro plaque-forming cell assays of antibody formation. The immunosuppression induced by both compounds could be blocked by SR144528, an antagonist specific for the CB 2 receptor, but not by SR141716, a CB 1 antagonist. These studies are novel in that they show that both anandamide and THC are active in the nanomolar to picomolar (for anandamide) range in these assays of immune function, and that both mediate their effects directly on cells of the immune system through the CB 2 receptor.
Introduction
Tetrahydrocannabinol (THC) has been shown to have marked effects on various parameters of immune function including inhibition of in vitro antibody formation by mouse spleen cells (Nahas et al., 1973; Kaminski et al., 1992) , suppression of lymphocyte proliferation driven by mitogens or IL-2 responses (Friedman et al., 1991; Kawakami et al., 1988) , inhibition of cytotoxic T cell and NK cell activity (Klein et al., 1991) , inhibition of macrophage antigen processing of certain proteins (McCoy et al., 1999) and inhibition of macrophage secretion of the proinflammatory cytokine TNF-α by a posttranslational mechanism (Fischer-Stenger et al., 1993; Zheng and Specter, 1996) . Evidence indicates that THC polarizes immune responses towards a Th2 phenotype (Lu et al., 2006) .
Cannabinoid research has seen marked advances with the cloning of two cannabinoid receptors designated, CB 1 and CB 2 (Matsuda et al., 1990; Munro et al., 1993) . The receptors are unevenly distributed in neural versus immune tissues, with mRNA for CB 1 expressed preferentially in the brain and other neural tissues, and to a lesser extent in peripheral immune tissues (Schatz et al., 1997; Galiegue et al., 1995) , whereas CB 2 is found primarily in cells of the immune system (Munro et al., 1993; Schatz et al., 1997), but not neurons. Microglia in the brain have been reported to express low levels of CB 1 constitutively, but to up-regulate CB 2 when activated (Cabral and Marciano-Cabral, 2005 ). An important area of investigation is the dissection of whether CB 1 or CB 2 receptors mediate various effects of Δ 9 -THC on the immune system. Discovery of endogenous ligands for the cannabinoid receptors, including anandamide (Devane et al., 1992) , has increased awareness of the potential importance of cannabinoids in homeostatic processes, including immune function. There are few studies showing direct effects of endogenous cannabinoids on CB 1 or CB 2 receptors in the immune system. Anandamide has been reported to stimulate growth of hematopoietic cell lines by a cannabinoid receptor-independent pathway (Derocq et al., 1998) , to induce apoptosis in a macrophage cell line via vanilloid receptors (Maccarrone et al., 2000) , and to induce 
